243 related articles for article (PubMed ID: 28847226)
21. Projecting Survival in Papillary Thyroid Cancer: A Comparison of the Seventh and Eighth Editions of the American Joint Commission on Cancer/Union for International Cancer Control Staging Systems in Two Contemporary National Patient Cohorts.
Pontius LN; Oyekunle TO; Thomas SM; Stang MT; Scheri RP; Roman SA; Sosa JA
Thyroid; 2017 Nov; 27(11):1408-1416. PubMed ID: 28891405
[TBL] [Abstract][Full Text] [Related]
22. The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer.
Wang F; Yu X; Shen X; Zhu G; Huang Y; Liu R; Viola D; Elisei R; Puxeddu E; Fugazzola L; Colombo C; Jarzab B; Czarniecka A; Lam AK; Mian C; Vianello F; Yip L; Riesco-Eizaguirre G; Santisteban P; O'Neill CJ; Sywak MS; Clifton-Bligh R; Bendlova B; Sýkorová V; Wang Y; Liu S; Zhao J; Zhao S; Xing M
J Clin Endocrinol Metab; 2017 Sep; 102(9):3241-3250. PubMed ID: 28582521
[TBL] [Abstract][Full Text] [Related]
23. Survival Analysis of Papillary Thyroid Carcinoma in Relation to Stage and Recurrence Risk: A 20-Year Experience in Pakistan.
Hassan A; Razi M; Riaz S; Khalid M; Nawaz MK; Syed AA; Bashir H
Clin Nucl Med; 2016 Aug; 41(8):606-13. PubMed ID: 27124680
[TBL] [Abstract][Full Text] [Related]
24. In differentiated thyroid cancer, an incomplete structural response to therapy is associated with significantly worse clinical outcomes than only an incomplete thyroglobulin response.
Vaisman F; Tala H; Grewal R; Tuttle RM
Thyroid; 2011 Dec; 21(12):1317-22. PubMed ID: 22136267
[TBL] [Abstract][Full Text] [Related]
25. Initial and Dynamic Risk Stratification of Pediatric Patients With Differentiated Thyroid Cancer.
Sung TY; Jeon MJ; Lee YH; Lee YM; Kwon H; Yoon JH; Chung KW; Kim WG; Song DE; Hong SJ
J Clin Endocrinol Metab; 2017 Mar; 102(3):793-800. PubMed ID: 27809646
[TBL] [Abstract][Full Text] [Related]
26. Disease Progression in Papillary Thyroid Cancer with Biochemical Incomplete Response to Initial Therapy.
Zern NK; Clifton-Bligh R; Gill AJ; Aniss A; Sidhu S; Delbridge L; Learoyd D; Robinson B; Sywak M
Ann Surg Oncol; 2017 Sep; 24(9):2611-2616. PubMed ID: 28585075
[TBL] [Abstract][Full Text] [Related]
27. Predictors for papillary thyroid cancer persistence and recurrence: a retrospective analysis with a 10-year follow-up cohort study.
de Castro TP; Waissmann W; Simões TC; de Mello RC; Carvalho DP
Clin Endocrinol (Oxf); 2016 Sep; 85(3):466-74. PubMed ID: 26834009
[TBL] [Abstract][Full Text] [Related]
28. Recurrence of papillary thyroid carcinoma with lateral cervical node metastases: Predictive factors and operative management.
Chéreau N; Buffet C; Trésallet C; Tissier F; Leenhardt L; Menegaux F
Surgery; 2016 Mar; 159(3):755-62. PubMed ID: 26435440
[TBL] [Abstract][Full Text] [Related]
29. High recurrent rate of multicentric papillary thyroid carcinoma.
Lin JD; Chao TC; Hsueh C; Kuo SF
Ann Surg Oncol; 2009 Sep; 16(9):2609-16. PubMed ID: 19533244
[TBL] [Abstract][Full Text] [Related]
30. Prognostic Implications of Lymph Node Yield in Central and Lateral Neck Dissections for Well-Differentiated Papillary Thyroid Carcinoma.
Heaton CM; Chang JL; Orloff LA
Thyroid; 2016 Mar; 26(3):434-40. PubMed ID: 26825749
[TBL] [Abstract][Full Text] [Related]
31. Higher administered activities of radioactive iodine are associated with less structural persistent response in older, but not younger, papillary thyroid cancer patients with lateral neck lymph node metastases.
Sabra MM; Grewal RK; Ghossein RA; Tuttle RM
Thyroid; 2014 Jul; 24(7):1088-95. PubMed ID: 24559250
[TBL] [Abstract][Full Text] [Related]
32. Microscopic positive margins in papillary thyroid cancer do not impact disease recurrence.
Abraham E; Tran B; Roshan D; Graham S; Lehane C; Wykes J; Campbell P; Ebrahimi A
ANZ J Surg; 2018 Nov; 88(11):1193-1197. PubMed ID: 29701284
[TBL] [Abstract][Full Text] [Related]
33. Excellent Prognosis of Central Lymph Node Recurrence-Free Survival for cN0M0 Papillary Thyroid Carcinoma Patients Who Underwent Routine Prophylactic Central Node Dissection.
Ito Y; Miyauchi A; Masuoka H; Fukushima M; Kihara M; Miya A
World J Surg; 2018 Aug; 42(8):2462-2468. PubMed ID: 29372373
[TBL] [Abstract][Full Text] [Related]
34. Treatment Outcomes and Risk Factors for Recurrence After Definitive Surgery of Locally Invasive Well-Differentiated Papillary Thyroid Carcinoma.
Kim JW; Roh JL; Gong G; Cho KJ; Choi SH; Nam SY; Kim SY
Thyroid; 2016 Feb; 26(2):262-70. PubMed ID: 26566765
[TBL] [Abstract][Full Text] [Related]
35. Differentiated thyroid carcinoma. Follow-up of 264 patients from one institution for up to 25 years.
Gemsenjäger E; Heitz PU; Seifert B; Martina B; Schweizer I
Swiss Med Wkly; 2001 Mar; 131(11-12):157-63. PubMed ID: 11416889
[TBL] [Abstract][Full Text] [Related]
36. Papillary thyroid carcinoma: factors influencing recurrence and survival.
Toniato A; Boschin I; Casara D; Mazzarotto R; Rubello D; Pelizzo M
Ann Surg Oncol; 2008 May; 15(5):1518-22. PubMed ID: 18324441
[TBL] [Abstract][Full Text] [Related]
37. Papillary thyroid carcinoma and microcarcinoma: is there a need to distinguish the two?
Arora N; Turbendian HK; Kato MA; Moo TA; Zarnegar R; Fahey TJ
Thyroid; 2009 May; 19(5):473-7. PubMed ID: 19348582
[TBL] [Abstract][Full Text] [Related]
38. Impact of nodal metastases on prognosis in patients with well-differentiated thyroid cancer.
Beasley NJ; Lee J; Eski S; Walfish P; Witterick I; Freeman JL
Arch Otolaryngol Head Neck Surg; 2002 Jul; 128(7):825-8. PubMed ID: 12117344
[TBL] [Abstract][Full Text] [Related]
39. Response to Treatment is Highly Predictable in cN0 Patients with Papillary Thyroid Carcinoma.
Gorshtein A; Benbassat C; Robenshtok E; Shimon I; Hirsch D
World J Surg; 2016 Sep; 40(9):2123-30. PubMed ID: 27094559
[TBL] [Abstract][Full Text] [Related]
40. Modified dynamic risk stratification system further predicts individual outcome in patients with intermediate-risk papillary thyroid cancer.
Cuéllar DI; De Los Reyes A; Llamas-Olier A
Ann Endocrinol (Paris); 2023 Apr; 84(2):242-248. PubMed ID: 35483449
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
